StimCardio raises $30M for wearable AFib therapy
StimCardio, a company developing wearables for atrial fibrillation, has secured $30 million in Series A funding. The round was led by John Slump’s family office, Metis Medtech, with participation from Catalyst Health Ventures and several corporate strategic investors, alongside new and existing backers.
Noninvasive Nerve Stimulation Device
The company’s product, Rhyvive, is a wrist-worn device designed to treat atrial fibrillation through noninvasive nerve stimulation. It combines ECG and optical sensors to collect physiological data with electrodes that deliver low-level electrical stimulation to the median nerve at the wrist. This stimulation aims to influence the nervous system pathways that regulate heart rhythm.
Rhyvive is currently under clinical investigation. It is intended for at-home use following a catheter ablation procedure, with the goal of reducing the recurrence of atrial fibrillation. The company plans to use the new investment to fund its NeuroPulse 2 study and prepare for a De Novo submission to the U.S. Food and Drug Administration (FDA).
CEO Statement and Market Context
“Our vision is to establish non-invasive neuromodulation as a new therapeutic category in cardiac electrophysiology,” said Amir Soltanianzadeh, CEO of StimCardio Medical. “This financing brings together investors with deep expertise in cardiac device innovation and provides the resources to deliver a first-of-its-kind, multicenter key study. With encouraging clinical evidence to date and a growing research program, we see an opportunity to extend treatment beyond the procedure room and improve outcomes for the millions of people living with AF.”
Wearable health devices have become more common. According to Rock Health’s 2025 Consumer Adoption of Digital Health Survey, 46% of U.S. adults now own a wearable, a significant increase from 13% in 2015. Major tech companies are also integrating cardiac health features into their devices.
The Apple Watch Series 12 includes options for ECG recordings and notifications for irregular heart rhythm and sleep apnea. It also features a hypertension notification that analyzes optical heart sensor data. Last year, the FDA cleared this hypertension notification feature for some Apple smartwatches. In 2024, the FDA also announced the Apple Watch atrial fibrillation feature qualified for use in clinical trials.
Google’s Pixel Watch 5 also contains optical heart rate and electrical sensors, enabling users to take ECG readings and check for signs of atrial fibrillation. While these devices detect and monitor a-fib, StimCardio’s wearable is designed to deliver nerve stimulation to reduce its recurrence.
